Word

CRINETICS PHARMACEUTICALS

Status

Dead

Status Code

602

Status Date

Tuesday, July 19, 2022

Serial Number

87875065

Mark Type

4000

Filing Date

Thursday, April 12, 2018

Published for Opposition

Tuesday, September 18, 2018

Abandoned Date

Wednesday, July 6, 2022

Trademark Owner History

Crinetics Pharmaceuticals, Inc. - Owner At Publication

Classifications

5 Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related cancers; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to treat or prevent dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; pharmaceuticals to target neuropeptide receptors; pharmaceuticals for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain

42 Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others

"PHARMACEUTICALS"

Trademark Events

Jul 19, 2022

Abandonment Notice E-Mailed - Failure To Respond

Jul 19, 2022

Abandonment - Failure To Respond Or Late Response

Jan 5, 2022

Notification Of Non-Final Action E-Mailed

Jan 5, 2022

Non-Final Action E-Mailed

Jan 5, 2022

Su - Non-Final Action - Written

Nov 30, 2021

Statement Of Use Processing Complete

Oct 29, 2021

Use Amendment Filed

Oct 29, 2021

Teas Statement Of Use Received

May 8, 2021

Notice Of Approval Of Extension Request E-Mailed

May 7, 2021

Sou Extension 5 Granted

Apr 29, 2021

Sou Extension 5 Filed

May 7, 2021

Case Assigned To Intent To Use Paralegal

Apr 29, 2021

Sou Teas Extension Received

Oct 30, 2020

Notice Of Approval Of Extension Request E-Mailed

Oct 28, 2020

Sou Extension 4 Granted

Oct 28, 2020

Sou Extension 4 Filed

Oct 28, 2020

Sou Teas Extension Received

Apr 28, 2020

Notice Of Approval Of Extension Request E-Mailed

Apr 24, 2020

Sou Extension 3 Granted

Apr 24, 2020

Sou Extension 3 Filed

Apr 24, 2020

Sou Teas Extension Received

Oct 23, 2019

Notice Of Approval Of Extension Request E-Mailed

Oct 21, 2019

Sou Extension 2 Granted

Oct 21, 2019

Sou Extension 2 Filed

Oct 21, 2019

Sou Teas Extension Received

Apr 19, 2019

Notice Of Approval Of Extension Request E-Mailed

Apr 17, 2019

Sou Extension 1 Granted

Apr 17, 2019

Sou Extension 1 Filed

Apr 17, 2019

Sou Teas Extension Received

Apr 17, 2019

Applicant/Correspondence Changes (Non-Responsive) Entered

Apr 17, 2019

Teas Change Of Owner Address Received

Nov 13, 2018

Noa E-Mailed - Sou Required From Applicant

Sep 18, 2018

Official Gazette Publication Confirmation E-Mailed

Sep 18, 2018

Published For Opposition

Aug 29, 2018

Notification Of Notice Of Publication E-Mailed

Aug 16, 2018

Assigned To Lie

Aug 6, 2018

Approved For Pub - Principal Register

Aug 6, 2018

Examiner's Amendment Entered

Aug 6, 2018

Notification Of Examiners Amendment E-Mailed

Aug 6, 2018

Examiners Amendment E-Mailed

Aug 6, 2018

Examiners Amendment -Written

Jul 31, 2018

Assigned To Examiner

Apr 21, 2018

New Application Office Supplied Data Entered

Apr 16, 2018

New Application Entered